- Conditions
- Breast Cancer
- Interventions
- Anastrozole (Arimidex), Goserelin (Zoladex)
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HCV Infection
- Interventions
- VCH 916, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Dallas, Texas • San Antonio, Texas
- Conditions
- Adult Solid Neoplasm
- Interventions
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib
- Biological · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation, Melanoma, NSCLC, Glioma, Solid Tumor, Adult, MAPK Pathway Gene Mutation
- Interventions
- NST-628
- Drug
- Lead sponsor
- Nested Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- San Francisco, California • Westwood, Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
- Interventions
- P-PSMA-101 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 6 more
- Conditions
- Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Post-Essential Thrombocythemia Related Myelofibrosis
- Interventions
- LBH589
- Drug
- Lead sponsor
- Ronald Hoffman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Interventions
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Boston, Massachusetts • Reno, Nevada + 4 more
- Conditions
- Healthy Volunteers
- Interventions
- VEL-101, Placebo
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy Volunteers
- Interventions
- MLN3126, MLN3126 Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Eatontown, New Jersey
- Conditions
- Advanced HER2+Breast Cancer
- Interventions
- Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Fayetteville, Arkansas • Los Angeles, California
- Conditions
- Locally Advanced Solid Tumor
- Interventions
- AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection
- Drug
- Lead sponsor
- Adlai Nortye Biopharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Lake Mary, Florida • New Brunswick, New Jersey + 2 more
- Conditions
- Cytomegalovirus Infections
- Interventions
- CMV-Peptide-Specific T cells
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neonatal Staphylococcal Sepsis
- Interventions
- Pagibaximab (formerly BSYX-A110)
- Drug
- Lead sponsor
- Biosynexus Incorporated
- Industry
- Eligibility
- 3 Days to 7 Days
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Meniere's Disease
- Interventions
- OTO-104 (steroid) 3 mg, Placebo, OTO-104 (steroid) 12 mg
- Drug
- Lead sponsor
- Otonomy, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • Colorado Springs, Colorado + 12 more
- Conditions
- Advanced Solid Tumor
- Interventions
- ZL-1211
- Drug
- Lead sponsor
- Zai Biopharmaceutical (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more
- Conditions
- Metastatic Neoplasm
- Interventions
- SAR441000, Cemiplimab REGN2810
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Houston, Texas
- Conditions
- Smoking Cessation
- Interventions
- Varenicline Tartrate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- East Grand Forks, Minnesota • Fargo, North Dakota
- Conditions
- Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Bladder Cancer
- Interventions
- Sacituzumab Govitecan (SG), Enfortumab vedotin-ejfv (EV), Pembrolizumab
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumors
- Interventions
- PF-03758309
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Aurora, Colorado
- Conditions
- MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Resmetirom
- Drug
- Lead sponsor
- Madrigal Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Advanced Solid Tumors
- Interventions
- Monalizumab, Durvalumab, Cetuximab, mFOLFOX6, Bevacizumab
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 19 more
- Conditions
- Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment
- Interventions
- SBRT
- Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
- Interventions
- KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
- Biological · Drug
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Rancho Santa Margarita, California • Weston, Florida + 12 more
- Conditions
- Neuropathic Pain
- Interventions
- KRN5500, Placebo
- Drug
- Lead sponsor
- DARA Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Orange, California • Jupiter, Florida + 7 more